NANOBOTS | Tumor-Targeting Nanoengineered Bioorthogonal Technologies to Fight Metastatic Cancers

Summary
Multifunctional nanodevices have recently emerged as one of the most exciting new classes of drug delivery machineries to perform abiotic prodrug activation in living systems. However, as current designs have not yet been configured with cell targeting capabilities, their use is limited to the targeting of non-metastatic primary cancers. This proposal, termed 'NANOBOTS', aims to develop an unprecedented ‘track and treat’ nanomachine installed with navigational ability to achieve cell-specific targeting and prodrug activation capabilities to treat metastatic cancers. The strategy involves the development of Pd-functionalized and tetrazine-based nanodevices specifically designed to (1) track & tag both metastatic lesions and primary tumours by identification of cell-surface proteins overexpressed in cancer cells, and to (2) activate systemically-administered cytotoxic precursors inside or at the surface of those cells via Pd-catalyzed deprotection or click-to-release chemistry. Using a range of multidisciplinary methods and techniques including Organometallic Chemistry, Medicinal Chemistry, Supramolecular Chemistry and Nanotechnology, I will develop multifunctional nanobots that will enable –for the first time- targeted treatment of metastatic lesions. Importantly, the modular feature of the nanobots provide a solid ground for a powerful breadth of future applications, e.g. exploiting an over-expressed surface protein in a new disease class as 'navigational guide' beyond cancer. With the support of a MSCA-IF, I will have the opportunity of performing a highly-innovative research programme within a chemistry lab based in the Cancer Research UK Edinburgh Centre, a world-class institution on cancer biology and therapy, and under the mentorship of Dr Unciti-Broceta, one of the pioneers of the Bioorthogonal Organometallic Chemistry field. This will certainly promote the translation of the results and enhance my professional growth towards my research independence.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/799874
Start date: 19-11-2018
End date: 18-11-2020
Total budget - Public funding: 183 454,80 Euro - 183 454,00 Euro
Cordis data

Original description

Multifunctional nanodevices have recently emerged as one of the most exciting new classes of drug delivery machineries to perform abiotic prodrug activation in living systems. However, as current designs have not yet been configured with cell targeting capabilities, their use is limited to the targeting of non-metastatic primary cancers. This proposal, termed 'NANOBOTS', aims to develop an unprecedented ‘track and treat’ nanomachine installed with navigational ability to achieve cell-specific targeting and prodrug activation capabilities to treat metastatic cancers. The strategy involves the development of Pd-functionalized and tetrazine-based nanodevices specifically designed to (1) track & tag both metastatic lesions and primary tumours by identification of cell-surface proteins overexpressed in cancer cells, and to (2) activate systemically-administered cytotoxic precursors inside or at the surface of those cells via Pd-catalyzed deprotection or click-to-release chemistry. Using a range of multidisciplinary methods and techniques including Organometallic Chemistry, Medicinal Chemistry, Supramolecular Chemistry and Nanotechnology, I will develop multifunctional nanobots that will enable –for the first time- targeted treatment of metastatic lesions. Importantly, the modular feature of the nanobots provide a solid ground for a powerful breadth of future applications, e.g. exploiting an over-expressed surface protein in a new disease class as 'navigational guide' beyond cancer. With the support of a MSCA-IF, I will have the opportunity of performing a highly-innovative research programme within a chemistry lab based in the Cancer Research UK Edinburgh Centre, a world-class institution on cancer biology and therapy, and under the mentorship of Dr Unciti-Broceta, one of the pioneers of the Bioorthogonal Organometallic Chemistry field. This will certainly promote the translation of the results and enhance my professional growth towards my research independence.

Status

CLOSED

Call topic

MSCA-IF-2017

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.2. Nurturing excellence by means of cross-border and cross-sector mobility
H2020-MSCA-IF-2017
MSCA-IF-2017